Acute Exacerbation of CRS Treatment Market Outlook, 2021-2031

Acute Exacerbation of CRS Treatment Market (Treatment: Antibiotics, Leukotriene Inhibitors, Antihistamines, Mucolytics, Decongestants, Nasal Saline Irrigation, Oral Corticosteroids, Endoscopic Sinus Surgery, and Others; Route of Administration: Topical, Nasal, Oral, and Injectable; Distribution Channel: Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies; and Infection Type: Staphylococcus Species and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Manufacturers Increase Availability of Treatment Options amid COVID-19 Pandemic

Acute exacerbation of CRS (Chronic Rhinosinusitis) is regarded as a serious airway disease. According to the World Health Organization (WHO) recommendations, it may be a risk factor for exposure to COVID-19 as well as for existing COVID-19 positive patients. Hence, companies in the acute exacerbation of CRS treatment market are increasing the availability of treatments and medicines to reduce morbidity and mortality of patients.

Manufacturers in the acute exacerbation of CRS treatment market are boosting their production capacities in intranasal corticosteroids that are considered as the gold standard for CRS in patients with coronavirus. Stakeholders are gaining awareness about reducing surgical treatments to the minimum. Treatment with biologics is being recommended with careful monitoring in non-infected patients and should be temporarily interrupted during COVID-19 infection.

acute exacerbation of crs treatment market infographic

Biologics Hold Promising Potentials for CRSwNP Patients Before Initial Surgery

CRS with nasal polyps (CRSwNP) is a common and heterogeneous inflammatory disease of the upper respiratory tract. Despite the potential value of biomarker-based endotyping to provide guidance regarding optimal care and treatment choices for patients with CRSwNP, the current practice is largely not biomarker-based. This explains why the acute exacerbation of CRS treatment market is slated to register a CAGR of 4.6% from 2021 to 2031. Hence, companies are now increasing focus on biologics, especially for patients before considering initial surgery.

Patients with comorbid severe asthma and for whom surgery is less available are opting for biologics. Biologics are being recommended for use immediately following surgery in patients who have a history of nasal polyp recurrence within 12 months of a prior surgery.

Antibiotics Help in Treatment of Patients with Severe Asthma, CRS

Severe asthma and acute exacerbation of CRS lead to frequent comorbidities, thus complicating the overall management of the disease. Biomarkers such as absolute eosinophil count in peripheral blood and fractional exhaled nitric oxide (FeNO) may be used as indicators of type 2 asthma endotypes and help predict response to biologic therapies.

There is data indicating that the presence of CRS is associated with worse outcomes in patients with asthma, more specifically with increased risk of frequent exacerbations. Hence, companies in the acute exacerbation of CRS treatment market are increasing their production capabilities in antibiotics, oral analgesics, and intranasal steroids, among other treatment options to improve patient outcomes.

Individualized Treatment with Antibiotics Improves Patient Quality of Life

Defining acute exacerbations of CRS with quantifiable clinical and immunologic metrics has remained a challenge due to the complex etiology of acute exacerbations and the inconsistency in endpoint reporting. Current recommendations for treatment of acute exacerbation of CRS continue to suggest blanket medical intervention, including short-course antibiotic treatment. Companies in the acute exacerbation of CRS treatment market are increasing R&D to improve methods for clinically defining the disease and its risk factors to facilitate individualized treatment.

Manufacturers in the acute exacerbation of CRS treatment market are boosting their output capacities in first-line antibiotic therapies such as amoxicillin, with or without clavulanate to improve patient quality of life.

acute exacerbation of crs treatment market segmentation

Analysts’ Viewpoint

Healthcare providers are closely monitoring the COVID-19 situation and have recommended aligning any diagnostic and treatment operations with guidance from the WHO and Centers for Disease Control and Prevention (CDC). The acute exacerbation of CRS treatment market is expected to reach US$ 7.06 Bn by 2031. Though available biological agents have therapeutic effects for patients with asthma and CRS, the improvement of nasal symptoms is less evident, despite reaching satisfactory asthma control. Hence, companies should improve their knowledge in potential therapeutic agents and increase the ability of biological agents to equally reach different tissues in order to improve patient outcomes.

Acute Exacerbation of CRS Treatment Market: Overview

  • Rhinosinusitis is a serious health issue that affects people all over the world. It's a sinus infection that starts in the nasal passages and spreads to the paranasal sinuses. Nasal blockage, purulent nasal discharge, and face pain-pressure-fullness are the three main symptoms. The patient defines nasal obstruction as obstruction, congestion, blockage, or stuffiness; purulent nasal discharge is hazy or colored in appearance; and facial pain-pressure-fullness affects the anterior face and periorbital area, or presents as headache that can be localized or widespread.
  • The acute exacerbation of CRS treatment market is anticipated to be driven by the increase in rhinosinusitis patients during the forecast period. In 2018, the CDC estimated that 28.9 million individuals in the U.S. were diagnosed with rhinosinusitis.

Acute Exacerbation of CRS Treatment: Market Drivers

  • Acute CRS exacerbation is gaining traction due of its considerable impact on patients' quality of life and healthcare costs. Acute CRS exacerbation is a kind of CRS that is started by viruses and subsequently followed by bacterial infections, which may be the result of a bacterial species imbalance inside the sinus cavities.
  • Understanding the etiology and immunological mechanisms of acute CRS exacerbation has increased significantly. However, there is currently no consensus definition, diagnostic criteria, biomarkers to distinguish acute CRS exacerbation from CRS, illness severity assessment, or evidence-based therapy choices for acute CRS exacerbation.
  • Rise in mucosal inflammation incidences leading to rhinosinusitis is expected to drive the demand for acute CRS exacerbation treatment over the next few years
  • Demand for acute CRS exacerbation treatment is expected to further increase due to rise in patient awareness about sinusitis treatment. New products and device development in the field of acute CRS exacerbation are also projected to significantly propel the market.

Surge in Product Launches and Approvals

  • In December 2020, AstraZeneca announced gaining marketing authorization from the Drugs Controller General of India (DCGI) for use of the original research medicine, Fasenra (Benralizumab solution, for injection in a single dose prefilled syringe30 mg/ml subcutaneous administration only) in patients with severe asthma (eosinophilic asthma) or chronic rhinosinusitis. Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients or patients with chronic rhinosinusitis. Rising number of product approvals is expected to drive the market during the forecast period.

Market Segmentation: Acute Exacerbation of CRS Treatment Market

  • In terms of treatment, the global acute exacerbation of CRS treatment market has been classified into antibiotics, leukotriene inhibitors, antihistamines, mucolytics, decongestants, nasal saline irrigation, oral corticosteroids, endoscopic sinus surgery, and others
  • In terms of route of administration, the global acute exacerbation of CRS treatment market has been segregated into topical, nasal, oral, and injectable
  • Based on distribution channel, the global acute exacerbation of CRS treatment market has been categorized into online pharmacies, retail pharmacies, and hospital pharmacies
  • Based on infection type, the global acute exacerbation of CRS treatment market has been bifurcated into staphylococcus species and others
  • Each of the segments has been analyzed in detail for acute exacerbation of CRS treatment trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The acute exacerbation of CRS treatment market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: Acute Exacerbation of CRS Treatment Market

  • In terms of region, the global acute exacerbation of CRS treatment market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.
  • North America accounted for a prominent share of the global market for acute exacerbation of CRS treatment in 2020. North America is expected to retain its market share during the forecast period primarily due to rise in cases of rhinosinusitis in the U.S. For instance, rhinosinusitis accounted for around 12 to 17 million annual visits to physicians and 12% of antibiotics prescribed to geriatric patients in the U.S., making it one of the 10 most common conditions to be treated in ambulatory practice. Hence, increase in cases of acute rhinosinusitis is projected to fuel the global acute exacerbation of CRS treatment market.
  • Asia Pacific is likely to increase its market share by the end of the forecast period. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by local players, especially in China and India, are anticipated to drive the acute exacerbation of CRS treatment market in the region. Surge in healthcare expenditure and rise in awareness about sinusitis are projected to drive the market in the region.
  • Demand for acute exacerbation of CRS treatment is also driven by expansion of major industries and the launch of acute exacerbation of CRS treatment by major companies in the region
  • Current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the report for the period from 2017 to 2031, along with their CAGRs for the period from 2021 to 2031
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which are estimated to help new companies willing to enter the market and existing companies to increase market share and in the decision-making process.

Major Players

  • The report concludes with the company profiles section that includes key information about the major players in the global acute exacerbation of CRS treatment market
  • Leading players analyzed in the report are
    • Sun Pharmaceutical Industries, Inc.
    • Pfizer Inc.
    • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
    • Fresenius Kabi USA, LLC
    • Dr. Reddy's Laboratories, Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Abbott Laboratories
    • Bayer AG
    • Eli Lilly And Company
    • Bristol-Myers Squibb
    • Merck & Co, Inc.
    • AstraZeneca Plc
    • Amneal Pharmaceuticals LLC
    • GlaxoSmithKline plc.
    • Aurobindo Pharma
    • Hikma Pharmaceuticals plc
    • Wockhardt
    • Mylan N.V.
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Acute Exacerbation of CRS Treatment Market – Segmentation

TMR’s study on the global acute exacerbation of CRS treatment market includes information divided into four segments: treatment, route of administration, distribution channel, infection type, and region.       

Treatment
  • Antibiotics
  • Leukotriene Inhibitors
  • Antihistamines
  • Mucolytics
  • Decongestants
  • Nasal Saline Irrigation
  • Oral Corticosteroids
  • Endoscopic sinus surgery
  • Others
Route of Administration
  • Topical
  • Nasal
  • Oral
  • Injectable
Distribution Channel
  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies
Infection Type
  • Staphylococcus Species
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Changing industry trends and other crucial market dynamics associated with these segments of the global acute exacerbation of CRS treatment market have been discussed in detail. 

Frequently Asked Questions

What is the total market worth of acute exacerbation of CRS treatment market?

Acute exacerbation of CRS treatment market to reach valuation of US$ 7.06 bn by 2031

What is the anticipated CAGR of the acute exacerbation of CRS treatment market in the forecast period?

Acute exacerbation of CRS treatment market is projected to expand at a CAGR of 4.6% from 2021 to 2031

What are the key driving factors for the growth of the acute exacerbation of CRS treatment market?

Acute exacerbation of CRS treatment market is driven by increase in instances of rhinosinusitis

Which region is expected to project the highest market share in the global acute exacerbation of CRS treatment market?

North America dominated the global acute exacerbation of CRS treatment market and the trend is anticipated to continue during the forecast period

Who are the key players in the global acute exacerbation of CRS treatment market?

Key players in the global acute exacerbation of CRS treatment market include Sun Pharmaceutical Industries, Inc., Pfizer Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Acute Exacerbation of CRS Treatment Market

    4. Market Overview

        4.1. Introduction & Overview

        4.2. Market Dynamics

            4.2.1. Drivers

            4.2.2. Restraints

            4.2.3. Opportunities

        4.3. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, 2017–2031

    5. Market Outlook

        5.1. Clinical Trials & Regulatory Approvals Analysis

        5.2. List of Brand / Product Approved

        5.3. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

        5.4. Technological Advancements

        5.5. Disease Prevalence & Incidence

    6. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Treatment

        6.1. Introduction & Definition

        6.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

            6.2.1. Acute Exacerbation of CRS

                6.2.1.1. Antibiotics

                6.2.1.2. Leukotriene Inhibitors

                6.2.1.3. Antihistamines

                6.2.1.4. Mucolytics

                6.2.1.5. Decongestants

                6.2.1.6. Nasal Saline Irrigation

                6.2.1.7. Oral Corticosteroids

                6.2.1.8. Endoscopic sinus surgery

                6.2.1.9. Others

        6.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Route of Administration

    7. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Route of Administration

        7.1. Introduction & Definition

        7.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration2017–2031 

            7.2.1. Acute Exacerbation of CRS

                7.2.1.1. Topical

                7.2.1.2. Nasal

                7.2.1.3. Oral

                7.2.1.4. Injectable   

        7.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Route of Administration

    8. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

            8.2.1. Acute Exacerbation of CRS   

                8.2.1.1. Online Pharmacies

                8.2.1.2. Retail Pharmacies

                8.2.1.3. Hospital Pharmacies         

        8.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Distribution Channel

    9. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Infection Type

        9.1. Introduction & Definition

        9.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

            9.2.1. Acute Exacerbation of CRS   

                9.2.1.1. Staphylococcus Species

                9.2.1.2. Others

        9.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Infection Type

    10. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Region

    11. North America Acute Exacerbation of CRS Treatment Market Analysis and Forecast

        11.1. Introduction

        11.2. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

            11.2.1. Acute Exacerbation of CRS

                11.2.1.1. Antibiotics

                11.2.1.2. Leukotriene Inhibitors

                11.2.1.3. Antihistamines

                11.2.1.4. Mucolytics

                11.2.1.5. Decongestants

                11.2.1.6. Nasal Saline Irrigation

                11.2.1.7. Oral Corticosteroids

                11.2.1.8. Endoscopic sinus surgery

                11.2.1.9. Others 

        11.3. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

            11.3.1. Acute Exacerbation of CRS

                11.3.1.1. Topical

                11.3.1.2. Nasal

                11.3.1.3. Oral

                11.3.1.4. Injectable 

        11.4. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

            11.4.1. Acute Exacerbation of CRS

                11.4.1.1. Online Pharmacies

                11.4.1.2. Retail Pharmacies

                11.4.1.3. Hospital Pharmacies 

        11.5. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

            11.5.1. Acute Exacerbation of CRS

                11.5.1.1. Staphylococcus Species

                11.5.1.2. Others   

        11.6. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. North America Acute Exacerbation of CRS Treatment Market Attractiveness Analysis

            11.7.1. By Treatment

            11.7.2. By Route of Administration

            11.7.3. By Distribution Channel

            11.7.4. Infection Type   

            11.7.5. By Country

    12. Europe Acute Exacerbation of CRS Treatment Market Analysis and Forecast

        12.1. Introduction

        12.2. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

            12.2.1. Acute Exacerbation of CRS

                12.2.1.1. Antibiotics

                12.2.1.2. Leukotriene Inhibitors

                12.2.1.3. Antihistamines

                12.2.1.4. Mucolytics

                12.2.1.5. Decongestants

                12.2.1.6. Nasal Saline Irrigation

                12.2.1.7. Oral Corticosteroids

                12.2.1.8. Endoscopic sinus surgery

                12.2.1.9. Others   

        12.3. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

            12.3.1. Acute Exacerbation of CRS

                12.3.1.1. Topical

                12.3.1.2. Nasal

                12.3.1.3. Oral

                12.3.1.4. Injectable

        12.4. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

            12.4.1. Acute Exacerbation of CRS

                12.4.1.1. Staphylococcus Species

                12.4.1.2. Others 

        12.5. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

            12.5.1. Germany

            12.5.2. U.K.

            12.5.3. France

            12.5.4. Spain

            12.5.5. Italy

            12.5.6. Rest of Europe

        12.6. Europe Acute Exacerbation of CRS Treatment Market Attractiveness Analysis

            12.6.1. By Treatment

            12.6.2. By Route of Administration

            12.6.3. By Distribution Channel

            12.6.4. By Infection Type

            12.6.5. By Country/Sub-region

    13. Asia Pacific Acute Exacerbation of CRS Treatment Market Analysis and Forecast

        13.1. Introduction

        13.2. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

            13.2.1. Acute Exacerbation of CRS

                13.2.1.1. Antibiotics

                13.2.1.2. Leukotriene Inhibitors

                13.2.1.3. Antihistamines

                13.2.1.4. Mucolytics

                13.2.1.5. Decongestants

                13.2.1.6. Nasal Saline Irrigation

                13.2.1.7. Oral Corticosteroids

                13.2.1.8. Endoscopic sinus surgery

                13.2.1.9. Others

        13.3. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

            13.3.1. Acute Exacerbation of CRS

                13.3.1.1. Topical

                13.3.1.2. Nasal

                13.3.1.3. Oral

                13.3.1.4. Injectable 

        13.4. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

            13.4.1. Acute Exacerbation of CRS

                13.4.1.1. Online Pharmacies

                13.4.1.2. Retail Pharmacies

                13.4.1.3. Hospital Pharmacies

        13.5. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

            13.5.1. China

            13.5.2. Japan

            13.5.3. India

            13.5.4. Australia & New Zealand

            13.5.5. Rest of Asia Pacific

        13.6. Asia Pacific Acute Exacerbation of CRS Treatment Market Attractiveness Analysis

            13.6.1. By Treatment

            13.6.2. By Route of Administration

            13.6.3. By Distribution Channel

            13.6.4. Infection Type

            13.6.5. By Country/Sub-region

    14. Latin America Acute Exacerbation of CRS Treatment Market Analysis and Forecast

        14.1. Introduction

        14.2. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

            14.2.1. Acute Exacerbation of CRS

                14.2.1.1. Antibiotics

                14.2.1.2. Leukotriene Inhibitors

                14.2.1.3. Antihistamines

                14.2.1.4. Mucolytics

                14.2.1.5. Decongestants

                14.2.1.6. Nasal Saline Irrigation

                14.2.1.7. Oral Corticosteroids

                14.2.1.8. Endoscopic sinus surgery

                14.2.1.9. Others

        14.3. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

            14.3.1. Acute Exacerbation of CRS

                14.3.1.1. Topical

                14.3.1.2. Nasal

                14.3.1.3. Oral

                14.3.1.4. Injectable

        14.4. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

            14.4.1. Acute Exacerbation of CRS

                14.4.1.1. Online Pharmacies

                14.4.1.2. Retail Pharmacies

                14.4.1.3. Hospital Pharmacies

        14.5. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

            14.5.1. Brazil

            14.5.2. Mexico

            14.5.3. Rest of Latin America

        14.6. Latin America Acute Exacerbation of CRS Treatment Market Attractiveness Analysis

            14.6.1. By Treatment

            14.6.2. By Route of Administration

            14.6.3. By Distribution Channel

            14.6.4. Infection Type

            14.6.5. By Country/Sub-region

    15. Middle East & Africa Acute Exacerbation of CRS Treatment Market Analysis and Forecast

        15.1. Introduction

        15.2. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

            15.2.1. Acute Exacerbation of CRS

                15.2.1.1. Antibiotics

                15.2.1.2. Leukotriene Inhibitors

                15.2.1.3. Antihistamines

                15.2.1.4. Mucolytics

                15.2.1.5. Decongestants

                15.2.1.6. Nasal Saline Irrigation

                15.2.1.7. Oral Corticosteroids

                15.2.1.8. Endoscopic sinus surgery

                15.2.1.9. Others

        15.3. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

            15.3.1. Acute Exacerbation of CRS

                15.3.1.1. Topical

                15.3.1.2. Nasal

                15.3.1.3. Oral

                15.3.1.4. Injectable

        15.4. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

            15.4.1. Acute Exacerbation of CRS

                15.4.1.1. Online Pharmacies

                15.4.1.2. Retail Pharmacies

                15.4.1.3. Hospital Pharmacies

        15.5. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

            15.5.1. Acute Exacerbation of CRS

                15.5.1.1. Staphylococcus Species

                15.5.1.2. Others

        15.6. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Middle East & Africa Acute Exacerbation of CRS Treatment Market Attractiveness Analysis

            15.7.1. By Treatment

            15.7.2. By Route of Administration

            15.7.3. By Distribution Channel

            15.7.4. By Infection Type

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Position Analysis, by Company, 2020

        16.2. Company Profiles

            16.2.1. Sun Pharmaceutical Industries, Inc.

                16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.1.2. Growth Strategies

                16.2.1.3. SWOT Analysis

            16.2.2. Pfizer Inc.

                16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.2.2. Growth Strategies

                16.2.2.3. SWOT Analysis

            16.2.3. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

                16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.3.2. Growth Strategies

                16.2.3.3. SWOT Analysis

            16.2.4. Fresenius Kabi USA, LLC.

                16.2.4.1. Company Overview (HQ, Business Segments)

                16.2.4.2. Growth Strategies

                16.2.4.3. SWOT Analysis

            16.2.5. Dr. Reddy's Laboratories, Inc.

                16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.5.2. Growth Strategies

                16.2.5.3. SWOT Analysis

            16.2.6. Novartis AG

                16.2.6.1. Company Overview (HQ, Business Segments)

                16.2.6.2. Growth Strategies

                16.2.6.3. SWOT Analysis

            16.2.7. Teva Pharmaceutical Industries Ltd

                16.2.7.1. Company Overview (HQ, Business Segments)

                16.2.7.2. Growth Strategies

                16.2.7.3. SWOT Analysis

            16.2.8. Sanofi

                16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.8.2. Growth Strategies

                16.2.8.3. SWOT Analysis

            16.2.9. Abbott Laboratories

                16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.9.2. Growth Strategies

                16.2.9.3. SWOT Analysis

            16.2.10. Bayer AG

                16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.10.2. Growth Strategies

                16.2.10.3. SWOT Analysis

            16.2.11. Eli Lilly And Company

                16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.11.2. Growth Strategies

                16.2.11.3. SWOT Analysis

            16.2.12. Bristol-Myers Squibb

                16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.12.2. Growth Strategies

                16.2.12.3. SWOT Analysis

            16.2.13. Merck & Co, Inc.

                16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.13.2. Growth Strategies

                16.2.13.3. SWOT Analysis

            16.2.14. AstraZeneca Plc

                16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.14.2. Growth Strategies

                16.2.14.3. SWOT Analysis

            16.2.15. Amneal Pharmaceuticals LLC

                16.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.15.2. Growth Strategies

                16.2.15.3. SWOT Analysis

            16.2.16. GlaxoSmithKline plc.

                16.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.16.2. Growth Strategies

                16.2.16.3. SWOT Analysis

            16.2.17. Aurobindo Pharma

                16.2.17.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.17.2. Growth Strategies

                16.2.17.3. SWOT Analysis

            16.2.18. Hikma Pharmaceuticals plc

                16.2.18.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.18.2. Growth Strategies

                16.2.18.3. SWOT Analysis

            16.2.19. Wockhardt

                16.2.19.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.19.2. Growth Strategies

                16.2.19.3. SWOT Analysis

            16.2.20. Mylan N.V. 

                16.2.20.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.20.2. Growth Strategies

                16.2.20.3. SWOT Analysis  

    List of Tables

    Table 01: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 02: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

    Table 03: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 04: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 05: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

    Table 06: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 07: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 08: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 09: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

    Table 10: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 11: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 12: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

    Table 13: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 15: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

    Table 16: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 17: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 18: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

    Table 19: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 20: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 21: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

    Table 22: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 23: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 24: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

    Table 25: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 26: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 27: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

    Table 28: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 29: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 30: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

    Table 31: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 32: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 33: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

    Table 34: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 35: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 36: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

    List of Figures

    Figure 01: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031

    Figure 03: Global Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031

    Figure 04: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Antibiotics, 2017–2031

    Figure 05: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Leukotriene Inhibitors, 2017–2031

    Figure 06: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Antihistamines, 2017–2031

    Figure 07: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Mucolytics, 2017–2031

    Figure 08: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Decongestants, 2017–2031

    Figure 09: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Nasal Saline Irrigation, 2017–2031

    Figure 10: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Oral Corticosteroids, 2017–2031

    Figure 11: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Endoscopic Sinus Surgery, 2017–2031

    Figure 12: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Others, 2017–2031

    Figure 13: Global Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 14: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 15: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Topical, 2017–2031

    Figure 16: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Nasal, 2017–2031

    Figure 17: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Oral, 2017–2031

    Figure 18: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Injectable, 2017–2031

    Figure 19: Global Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 20: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 21: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Online Pharmacies, 2017-2031

    Figure 22: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Retail Pharmacies, 2017-2031

    Figure 23: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Online Pharmacies, 2017-2031

    Figure 24: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Retail Pharmacies, 2017-2031

    Figure 25: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Hospital Pharmacies, 2017-2031

    Figure 26: Global Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031

    Figure 27: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031

    Figure 28: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Staphylococcus Species, 2017–2031

    Figure 29: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Others, 2017–2031

    Figure 30: Global Acute Exacerbation of CRS Market Value Share Analysis, by Region, 2020 and 2031

    Figure 31: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Region, 2021–2031

    Figure 32: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 33: North America Acute Exacerbation of CRS Market Value Share, by Country, 2020 and 2031

    Figure 34: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Country, 2021–2031

    Figure 35: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031

    Figure 36: North America Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031

    Figure 37: North America Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 38: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 39: North America Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 40: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 41: North America Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031

    Figure 42: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031

    Figure 43: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 44: Europe Acute Exacerbation of CRS Market Value Share, by Country/Sub-region, 2020 and 2031

    Figure 45: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 46: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031

    Figure 47: Europe Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031

    Figure 48: Europe Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 49: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 50: Europe Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 51: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 52: Europe Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031

    Figure 53: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031

    Figure 54: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 55: Asia Pacific Acute Exacerbation of CRS Market Value Share, by Country/Sub-region, 2020 and 2031

    Figure 56: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 57: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031

    Figure 58: Asia Pacific Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031

    Figure 59: Asia Pacific Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 60: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 61: Asia Pacific Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 62: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 63: Asia Pacific Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031

    Figure 64: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031

    Figure 65: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 66: Latin America Acute Exacerbation of CRS Market Value Share, by Country/Sub-region, 2020 and 2031

    Figure 67: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 68: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031

    Figure 69: Latin America Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031

    Figure 70: Latin America Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 71: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 72: Latin America Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 73: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 74: Latin America Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031

    Figure 75: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031

    Figure 76: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 77: Middle East & Africa Acute Exacerbation of CRS Market Value Share, by Country/Sub-region, 2020 and 2031

    Figure 78: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 79: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031

    Figure 80: Middle East & Africa Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031

    Figure 81: Middle East & Africa Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 82: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 83: Middle East & Africa Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 84: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 85: Middle East & Africa Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031

    Figure 86: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031

Copyright © Transparency Market Research, Inc. All Rights reserved